These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22542448)

  • 1. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
    Foss F; Horwitz SM; Coiffier B; Bartlett N; Popplewell L; Pro B; Pinter-Brown LC; Shustov A; Furman RR; Haioun C; Koutsoukos T; O'Connor OA
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):238-43. PubMed ID: 22542448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
    Talpur R; Thompson A; Gangar P; Duvic M
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
    J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
    Shimanovsky A; Dasanu CA
    Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.
    Azzoli CG; Patel JD; Krug LM; Miller V; James L; Kris MG; Ginsberg M; Subzwari S; Tyson L; Dunne M; May J; Huntington M; Saunders M; Sirotnak FM
    J Thorac Oncol; 2011 Nov; 6(11):1915-22. PubMed ID: 21841501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
    Duvic M; Kim YH; Zinzani PL; Horwitz SM
    Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML; Koutsoukos T; Saunders ME; O'Connor OA; Duvic M
    Blood; 2012 May; 119(18):4115-22. PubMed ID: 22394596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
    Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
    Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
    Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
    Foss FM
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
    Parker T; Barbarotta L; Foss F
    Future Oncol; 2013 Jan; 9(1):21-9. PubMed ID: 23252560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
    Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
    Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
    Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
    Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralatrexate for refractory mycosis fungoides in two Japanese patients.
    Teraishi M; Oguro T; Kusume E; Kobashi H; Sano H; Fujioka A; Yamamoto M; Nakajima H; Sano S
    J Dermatol; 2021 May; 48(5):667-671. PubMed ID: 33454985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.
    Kelly KR; Gabrail N; Weitman S; Sarantopoulos J; Olszanski AJ; Edenfield W; Venitz J; Reddy G; Yang A; Hasal SJ; Lockhart AC
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):929-939. PubMed ID: 27638045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
    Koch E; Story SK; Geskin LJ
    Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
    Azzoli CG; Krug LM; Gomez J; Miller VA; Kris MG; Ginsberg MS; Henry R; Jones J; Tyson L; Dunne M; Pizzo B; Farmer A; Venkatraman E; Steffen R; Sirotnak FM
    Clin Cancer Res; 2007 May; 13(9):2692-8. PubMed ID: 17473201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
    O'Connor OA; Horwitz S; Hamlin P; Portlock C; Moskowitz CH; Sarasohn D; Neylon E; Mastrella J; Hamelers R; Macgregor-Cortelli B; Patterson M; Seshan VE; Sirotnak F; Fleisher M; Mould DR; Saunders M; Zelenetz AD
    J Clin Oncol; 2009 Sep; 27(26):4357-64. PubMed ID: 19652067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.